Evidence map›Paper›PMID 34292882›Full record

ArticleThe Journal of clinical investigation2021

Gain-of-function mutation in ubiquitin-ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues.

Mathilde Csc Vermeer, Maria C Bolling, Jacqueline M Bliley, Karla F Arevalo Gomez, Mario G Pavez-Giani, Duco Kramer, Pedro H Romero-Herrera, B Daan Westenbrink, Gilles Fh Diercks, Maarten P van den Berg and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Novel compound heterozygous mutations inFrontiers in cardiovascular medicine · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. EBS in Children with De Novo Pathogenic Variants DisturbingInternational journal of molecular sciences · 2024
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Clinical Outcome inCirculation. Genomic and precision medicine · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Mathilde Csc VermeerDepartment of Cardiology, University Medical Center Groningen, Groningen, Netherlands.
Maria C BollingDepartment of Dermatology, University Medical Center Groningen, Groningen, Netherlands.
Jacqueline M BlileyDepartment of Biomedical Engineering, Department of Materials Science & Eng, Carnegie Mellon University, Pittsburgh, United States of America.
Karla F Arevalo GomezDepartment of Cardiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands.
Mario G Pavez-GianiDepartment of Cardiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands.
Duco KramerDepartment of Dermatology, University Medical Center Groningen, Groningen, Netherlands.
Pedro H Romero-HerreraDepartment of Cardiology, University Medical Center Groningen, Groningen, Netherlands.
B Daan WestenbrinkDepartment of Cardiology, University Medical Center Groningen, Groningen, Netherlands.
Gilles Fh DiercksDepartment of Pathology, University Medical Center Groningen, Groningen, Netherlands.
Maarten P van den BergDepartment of Cardiology, University Medical Center Groningen, Groningen, Netherlands.
Adam W FeinbergDepartment of Biomedical Engineering, Department of Materials Science & Eng, Carnegie Mellon University, Pittsburgh, United States of America.
Herman H W SilljéDepartment of Cardiology, University Medical Center Groningen, Groningen, Netherlands.
Peter van der MeerDepartment of Cardiology, University Medical Center Groningen, Groningen, Netherlands.
University Medical Center Groningen · NLCarnegie Mellon University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The start codon c.1A>G mutation in KLHL24, encoding ubiquitin-ligase KLHL24, results in the loss of 28 N-terminal amino acids (KLHL24-ΔN28) by skipping the initial start codon. In skin, KLHL24-ΔN28 leads to gain of function, excessively targeting intermediate filament keratin-14 for proteasomal degradation, ultimately causing epidermolysis bullosa simplex (EBS). The majority of these EBS-patients are also diagnosed with dilated cardiomyopathy (DCM), but the pathological mechanism in the heart is unknown. As desmin is the cardiac homologue of keratin-14, we hypothesized that KLHL24-ΔN28 leads to excessive degradation of desmin, resulting in DCM. Dynamically loaded engineered heart tissues (dyn-EHTs) were generated from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes from two patients and three (non)familial controls. Ten-fold lower desmin protein levels were observed in patient-derived dyn-EHTs, in line with diminished desmin levels detected in patients' explanted heart. This was accompanied by tissue dilatation, impaired mitochondrial function, decreased force values and increased cardiomyocyte stress. HEK293 transfection studies confirmed KLHL24-mediated desmin degradation. KLHL24 RNA interference or direct desmin overexpression recovered desmin protein levels, restoring morphology and function in patient-derived dyn-EHTs. To conclude, presence of KLHL24-ΔN28 in cardiomyocytes leads to excessive degradation of desmin, affecting tissue morphology and function, that can be prevented by restoring desmin protein levels.

Indexed as

CardiologyHeart failureiPS cellsUbiquitin-proteosome system

Identifiers

PMID34292882
PMCPMC8409593
OpenAlexW3183251333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.